In 2024, the U.S. Drug Enforcement Administration (DEA) indicated they intend to reclassify cannabis to be a Schedule III drug. This rescheduling will recognize that cannabis has legitimate health-related reasons and can help open up the door to investigate on other possible treatment uses. F